# Voyager Therapeutics, Inc.: financial statements, quarterly

VYGR · Nasdaq · CIK 1640266 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vygr.md) · [Financials](/companies/vygr/financials.md) · [Filings](/companies/vygr/filings.md) · [Insiders](/companies/vygr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vygr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [4.6](/filings/0001558370-24-015304.md) | [90.1 d](/filings/0001104659-26-025197.md) | [19.5](/filings/0001558370-25-006484.md) | [29.6](/filings/0001558370-25-010511.md) | [24.6](/filings/0001104659-25-108846.md) | [6.3 d](/filings/0001104659-26-025197.md) | [6.5](/filings/0001104659-26-057097.md) | [5.2](/filings/0001640266-26-000006.md) | [13.4](/filings/0001104659-25-108846.md) | [15.3 d](/filings/0001104659-26-025197.md) | [2.6](/filings/0001104659-26-057097.md) | [3.2](/filings/0001640266-26-000006.md) |
| Research and development | $m | [25.9](/filings/0001558370-24-015304.md) | [25.8 d](/filings/0001104659-26-025197.md) | [27.1](/filings/0001558370-25-006484.md) | [34.5](/filings/0001558370-25-010511.md) | [30.2](/filings/0001104659-25-108846.md) | [35.6 d](/filings/0001104659-26-025197.md) | [31.5](/filings/0001104659-26-057097.md) | [31.3](/filings/0001640266-26-000006.md) | [35.9](/filings/0001104659-25-108846.md) | [36.0 d](/filings/0001104659-26-025197.md) | [24.6](/filings/0001104659-26-057097.md) | [22.0](/filings/0001640266-26-000006.md) |
| Operating income | $m | [(29.5)](/filings/0001558370-24-015304.md) | [54.1 d](/filings/0001104659-26-025197.md) | [(16.2)](/filings/0001558370-25-006484.md) | [(15.0)](/filings/0001558370-25-010511.md) | [(13.8)](/filings/0001104659-25-108846.md) | [(38.3) d](/filings/0001104659-26-025197.md) | [(34.7)](/filings/0001104659-26-057097.md) | [(36.6)](/filings/0001640266-26-000006.md) | [(30.6)](/filings/0001104659-25-108846.md) | [(29.9) d](/filings/0001104659-26-025197.md) | [(30.3)](/filings/0001104659-26-057097.md) | [(26.4)](/filings/0001640266-26-000006.md) |
| Income tax | $m | [(0.2)](/filings/0001558370-24-015304.md) | [0.8 d](/filings/0001104659-26-025197.md) | [0.0](/filings/0001558370-25-006484.md) | [0.0](/filings/0001558370-25-010511.md) | [0.0](/filings/0001104659-25-108846.md) | [0.6 d](/filings/0001104659-26-025197.md) | [0.0](/filings/0001104659-26-057097.md) | [0.0](/filings/0001640266-26-000006.md) | [0.1](/filings/0001104659-25-108846.md) | [0.0 d](/filings/0001104659-26-025197.md) | [0.0](/filings/0001104659-26-057097.md) | [0.0](/filings/0001640266-26-000006.md) |
| Net income | $m | [(25.9)](/filings/0001558370-24-015304.md) | [56.4 d](/filings/0001104659-26-025197.md) | [(11.3)](/filings/0001104659-25-108846.md) | [(10.1)](/filings/0001104659-25-108846.md) | [(9.0)](/filings/0001104659-25-108846.md) | [(34.5) d](/filings/0001104659-26-025197.md) | [(31.0)](/filings/0001640266-26-000006.md) | [(33.4)](/filings/0001640266-26-000006.md) | [(27.9)](/filings/0001104659-25-108846.md) | [(27.4) d](/filings/0001104659-26-025197.md) | [(27.9)](/filings/0001640266-26-000006.md) | [(24.5)](/filings/0001640266-26-000006.md) |
| Diluted EPS | $ per share | [(0.59)](/filings/0001558370-24-015304.md) | not reported | [(0.20)](/filings/0001558370-25-006484.md) | [(0.18)](/filings/0001558370-25-010511.md) | [(0.16)](/filings/0001104659-25-108846.md) | not reported | [(0.53)](/filings/0001104659-26-057097.md) | [(0.57)](/filings/0001640266-26-000006.md) | [(0.47)](/filings/0001104659-25-108846.md) | not reported | [(0.47)](/filings/0001104659-26-057097.md) | [(0.40)](/filings/0001640266-26-000006.md) |
| Basic EPS | $ per share | [(0.59)](/filings/0001558370-24-015304.md) | not reported | [(0.20)](/filings/0001558370-25-006484.md) | [(0.18)](/filings/0001558370-25-010511.md) | [(0.16)](/filings/0001104659-25-108846.md) | not reported | [(0.53)](/filings/0001104659-26-057097.md) | [(0.57)](/filings/0001640266-26-000006.md) | [(0.47)](/filings/0001104659-25-108846.md) | not reported | [(0.47)](/filings/0001104659-26-057097.md) | [(0.40)](/filings/0001640266-26-000006.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [65.3](/filings/0001558370-23-017754.md) | [68.8](/filings/0001558370-25-002703.md) | [143](/filings/0001558370-24-007953.md) | [76.1](/filings/0001558370-24-011073.md) | [113](/filings/0001558370-24-015304.md) | [71.4](/filings/0001104659-26-025197.md) | [74.8](/filings/0001558370-25-006484.md) | [43.9](/filings/0001558370-25-010511.md) | [45.1](/filings/0001104659-25-108846.md) | [65.3](/filings/0001640266-26-000006.md) | [43.3](/filings/0001104659-26-057097.md) | [35.8](/filings/0001640266-26-000006.md) |
| Current assets | $m | [262](/filings/0001558370-23-017754.md) | [320](/filings/0001558370-25-002703.md) | [409](/filings/0001558370-24-007953.md) | [382](/filings/0001558370-24-011073.md) | [373](/filings/0001558370-24-015304.md) | [277](/filings/0001104659-26-025197.md) | [245](/filings/0001558370-25-006484.md) | [228](/filings/0001558370-25-010511.md) | [220](/filings/0001104659-25-108846.md) | [203](/filings/0001640266-26-000006.md) | [147](/filings/0001104659-26-057097.md) | [125](/filings/0001640266-26-000006.md) |
| Total assets | $m | [295](/filings/0001558370-23-017754.md) | [351](/filings/0001558370-25-002703.md) | [470](/filings/0001558370-24-007953.md) | [436](/filings/0001558370-24-011073.md) | [426](/filings/0001558370-24-015304.md) | [393](/filings/0001104659-26-025197.md) | [353](/filings/0001558370-25-006484.md) | [322](/filings/0001558370-25-010511.md) | [288](/filings/0001104659-25-108846.md) | [252](/filings/0001640266-26-000006.md) | [219](/filings/0001104659-26-057097.md) | [198](/filings/0001640266-26-000006.md) |
| Current liabilities | $m | [61.7](/filings/0001558370-23-017754.md) | [64.5](/filings/0001558370-25-002703.md) | [72.6](/filings/0001558370-24-007953.md) | [40.1](/filings/0001558370-24-011073.md) | [44.2](/filings/0001558370-24-015304.md) | [49.8](/filings/0001104659-26-025197.md) | [40.2](/filings/0001558370-25-006484.md) | [42.0](/filings/0001558370-25-010511.md) | [35.5](/filings/0001104659-25-108846.md) | [26.5](/filings/0001640266-26-000006.md) | [17.5](/filings/0001104659-26-057097.md) | [16.7](/filings/0001640266-26-000006.md) |
| Total liabilities | $m | [118](/filings/0001558370-23-017754.md) | [115](/filings/0001558370-25-002703.md) | [129](/filings/0001558370-24-007953.md) | [101](/filings/0001558370-24-011073.md) | [95.7](/filings/0001558370-24-015304.md) | [93.3](/filings/0001104659-26-025197.md) | [80.5](/filings/0001558370-25-006484.md) | [78.2](/filings/0001558370-25-010511.md) | [68.5](/filings/0001104659-25-108846.md) | [56.2](/filings/0001640266-26-000006.md) | [45.7](/filings/0001104659-26-057097.md) | [43.4](/filings/0001640266-26-000006.md) |
| Shareholders' equity | $m | [176](/filings/0001558370-24-015304.md) | [236](/filings/0001104659-26-025197.md) | [341](/filings/0001104659-25-108846.md) | [335](/filings/0001104659-25-108846.md) | [330](/filings/0001104659-25-108846.md) | [300](/filings/0001640266-26-000006.md) | [273](/filings/0001640266-26-000006.md) | [244](/filings/0001640266-26-000006.md) | [220](/filings/0001104659-25-108846.md) | [196](/filings/0001640266-26-000006.md) | [174](/filings/0001640266-26-000006.md) | [154](/filings/0001640266-26-000006.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(21.1) d](/filings/0001558370-24-015304.md) | [(23.8) d](/filings/0001104659-26-025197.md) | [58.8](/filings/0001558370-25-006484.md) | [(31.6) d](/filings/0001558370-25-010511.md) | [(28.0) d](/filings/0001104659-25-108846.md) | [(14.5) d](/filings/0001104659-26-025197.md) | [(37.9)](/filings/0001104659-26-057097.md) | [(33.3) d](/filings/0001640266-26-000006.md) | [(31.0) d](/filings/0001104659-25-108846.md) | [(30.3) d](/filings/0001104659-26-025197.md) | [(33.4)](/filings/0001104659-26-057097.md) | [(25.8) d](/filings/0001640266-26-000006.md) |
| Capital expenditure | $m | [0.8 d](/filings/0001558370-24-015304.md) | [0.8 d](/filings/0001104659-26-025197.md) | [2.1](/filings/0001558370-25-006484.md) | [1.0 d](/filings/0001558370-25-010511.md) | [0.3 d](/filings/0001104659-25-108846.md) | [0.2 d](/filings/0001104659-26-025197.md) | [0.7](/filings/0001104659-26-057097.md) | [1.1 d](/filings/0001640266-26-000006.md) | [0.2 d](/filings/0001104659-25-108846.md) | [0.6 d](/filings/0001104659-26-025197.md) | [0.0](/filings/0001104659-26-057097.md) | [0.0 d](/filings/0001640266-26-000006.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [39.6](/filings/0001558370-23-017754.md) | [42.2](/filings/0001558370-24-007953.md) | [43.5](/filings/0001558370-24-011073.md) | [43.9](/filings/0001558370-24-015304.md) | [57.1](/filings/0001558370-25-006484.md) | [57.7](/filings/0001558370-25-010511.md) | [57.9](/filings/0001104659-25-108846.md) | [58.3](/filings/0001104659-26-057097.md) | [58.7](/filings/0001640266-26-000006.md) | [58.8](/filings/0001104659-25-108846.md) | [59.5](/filings/0001104659-26-057097.md) | [60.5](/filings/0001640266-26-000006.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 61,617,948 at 2026-07-30, from the cover of the [10-Q filed 2026-08-06](/filings/0001640266-26-000006.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.